Phenotypes associated with this allele
skeleton
N |
• mice exhibit normal bone formation and osteoblast surface/numbers
|
|
• decreased proliferation of osteoclast precursors
|
|
• more trabecular bone and bone surface at 6 months
|
|
• with reduced spacing at 6 months
|
hematopoietic system
|
• decreased proliferation of osteoclast precursors
|
immune system
|
• decreased proliferation of osteoclast precursors
|
skeleton
N |
• doxycycline-treated mice exhibit normal numbers of osteoblasts, bone formation and bone mineral apposition rates
|
|
• in doxycycline-treated mice
|
|
• doxycycline-treated bone marrow cultures exhibit reduced osteoclast precursor proliferation compared with control cultures
|
|
• decreased bone surface in doxycycline-treated mice
|
|
• trabecular, cortical and total in doxycycline-treated mice
|
|
• with increased spacing in doxycycline-treated mice
|
|
• in doxycycline-treated mice
|
|
• in doxycycline-treated mice
|
|
• in doxycycline-treated mice
|
|
• in doxycycline-treated mice
|
hematopoietic system
|
• in doxycycline-treated mice
|
|
• doxycycline-treated bone marrow cultures exhibit reduced osteoclast precursor proliferation compared with control cultures
|
immune system
|
• in doxycycline-treated mice
|
|
• doxycycline-treated bone marrow cultures exhibit reduced osteoclast precursor proliferation compared with control cultures
|
skeleton
|
• cultured bone marrow cells contain fewer osteoclast precursors compared with control mice
|
hematopoietic system
|
• cultured bone marrow cells contain fewer osteoclast precursors compared with control mice
|
cellular
|
• cultured bone marrow cells contain fewer osteoclast precursors compared with control mice
|
immune system
|
• cultured bone marrow cells contain fewer osteoclast precursors compared with control mice
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ctnnb1tm1Mmt mutation
(0 available);
any
Ctnnb1 mutation
(49 available)
Ppargtm1.1(tTA)Jmgr mutation
(1 available);
any
Pparg mutation
(39 available)
Tg(tetO-cre)1Jaw mutation
(5 available)
|
|
|
skeleton
N |
• doxycycline-treated mice exhibit normal bone formation and numbers of osteoblasts
|
|
• impaired in doxycycline-treated mice
|
|
• in doxycycline-treated mice
|
|
• as early as P15 in doxycycline-treated mice
• 27-fold from 10 months of age in doxycycline-treated mice
|
|
• in doxycycline-treated mice
|
|
• 4.6-fold increase in trabecular bone surface and a smaller bone surface to bone volume in doxycycline-treated mice
|
|
• trabecular, cortical and total volume as early as P15 in doxycycline-treated mice
|
|
• 3.6-fold with reduced trabecular separation in doxycycline-treated mice
|
|
• 8.5-fold in doxycycline-treated mice
|
|
• severe in doxycycline-treated mice
• in mice following adult onset activation with doxycycline
|
|
• in doxycycline-treated mice
|
hematopoietic system
|
• impaired in doxycycline-treated mice
|
|
• in doxycycline-treated mice
|
|
• at 4 months in doxycycline-treated mice
|
|
• at 10 months in doxycycline-treated mice
|
|
• in doxycycline-treated mice
|
|
• gradual in doxycycline-treated mice
|
cellular
|
• impaired in doxycycline-treated mice
|
immune system
|
• impaired in doxycycline-treated mice
|
|
• in doxycycline-treated mice
|
|
• gradual in doxycycline-treated mice
|